Abstract
BACKGROUND: The assessment of Bevacizumab efficacy in high-grade gliomas (HGG) depends on the response criteria used, with discrepancies between T1 Gadolinium-enhanced sequences, T2 sequences and neurological outcome. The aim was to compare McDonald's, RANO and RECIST 1.1 criteria to the clinical outcome in a consecutive series of HGG patients. METHODS: HGG patients treated at the Montpellier Cancer Institute were retrospectively selected. Patients with a Performance Status (PS) 20% of the product of perpendicular diameters. CONCLUSIONS: The high correlation between McDonald's and RANO criteria demonstrates the importance of accurately assessing changes in steroids and neurological state, as well as imaging response, in order to avoid concluding to a false efficacy on imaging only, when using the McDonald's criteria. These results raise the question of the value of the FLAIR assessment when McDonald's criteria are rigorously applied.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
